SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to CRL and its shareholders. What can I do?   If you are a current Charles River shareholder, you may have legal claims that may be brought on behalf of the company, against CRL’s directors and officers. If you wish ...

Charles River Laboratories International, Inc. (CRL) is well-poised for the coming quarters, on the back of its impressive strategic acquisitions. Stabilization of demand trends within the DSA (Discovery and Safety Assessment) arm is encouraging. The company's sound solvency also instils optimism. However, concerns remain over the adverse impacts of macroeconomic challenges as well as currency fluctuations. In the past year, this Zacks Rank #3 (Hold) company's shares have risen 9.4% compared with 6.1% growt ...

Charles River Laboratories’ (CRL) Research Models and Services (RMS) arm continues to gain from the CRADL initiative. Yet, destocking efforts are denting growth in the Manufacturing Solutions business. The stock carries a Zacks Rank #3 (Hold) currently.Within Charles River’s RMS segment, the company is witnessing strong growth in the insourcing solutions (IS) business led by the CRADL (Charles River Accelerator and Development Labs) initiative. These days, clients are increasingly adopting CRADL’s flexible ...

Have you looked into how Charles River Laboratories (CRL) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this medical research equipment and services provider, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Sc ...

Charles River Laboratories International, Inc. (CRL) reported first-quarter 2024 adjusted earnings per share (EPS) of $2.27, which reflected an 18.3% decrease year over year. However, the metric surpassed the Zacks Consensus Estimate by 10.7%.On a GAAP basis, earnings declined 35.3% year over year to $1.30 per share. The year-over-year decline in GAAP earnings was primarily due to lower revenues and gross and operating income.RevenuesRevenues in the first quarter totaled $1.01 billion, beating the Zacks Con ...

财务数据和关键指标变化 - 公司第一季度收入为10.1亿美元,同比下降1.7% [16] - 有机收入下降3.3%,主要由于DSA业务收入下降抵消了制造和RMS业务的良好表现 [16][17] - 毛利率下降270个基点至18.5%,主要由于DSA业务毛利率下降以及未分配的企业成本上升 [17] - 每股收益为2.27美元,同比下降18.3% [18] 各条业务线数据和关键指标变化 DSA业务 - DSA业务收入为6.055亿美元,有机下降8.7% [20] - Discovery Services和Safety Assessment业务收入均有所下降 [20] - 安全评估业务的提案活动和取消率有所改善,但尚未完全转化为订单增长 [21] - DSA业务毛利率为23.5%,同比下降550个基点 [23] RMS业务 - RMS业务收入为2.209亿美元,有机增长3.3% [24] - 小型研究模型和NHP业务收入增长,服务业务收入小幅增长 [24][25][26] - RMS业务毛利率为27.6%,同比提升420个基点 [28] 制造解决方案业务 - 制造解决方案业务收入为1.852亿美元,有机增长10.4% [28] - 生物制品检测和微生物解决方案业务反弹,CDMO业务保持强劲增长 [29][30][31][34] - 制造解决方案业务毛利率为25.3%,同比大幅提升 [35] 各个市场数据和关键指标变化 - 小型和中型生物技术公司收入有所下降,但大型制药和学术客户收入有所增长 [17] - 中国市场研究模型业务增长放缓,但仍保持韧性 [25] 公司战略和发展方向 - 公司推出AMAP计划,未来5年将投资3亿美元开发替代动物技术 [37][38][39][40] - 公司将继续领导行业向更可持续的未来发展 [41] 管理层对经营环境和未来前景的评论 - 生物技术融资大幅增加,行业情绪有所改善,为公司带来积极影响 [9][10][15] - 公司对下半年需求改善保持谨慎乐观,但需要一定时间转化为新订单和收入 [10][11][14][15] - 长期行业基本面保持良好,公司作为行业领导者将从中受益 [14][15] - 潜在的BIOSECURE法案可能为公司带来净正面影响,但尚不确定具体影响程度 [13][14] 问答环节重要的提问和回答 问题1 **Max Smock 提问** 询问价格调整的原因和影响 [66][67][68][69][70] **Flavia Pease 回答** 解释价格调整对毛利率的影响,以及随着需求恢复和成本节约措施实施,毛利率将在下半年改善 [73][74] 问题2 **Dave Windley 提问** 询问价格和通胀的关系以及对未来的影响 [77][78][79][80] **Flavia Pease 回答** 解释价格和通胀的关系变化,以及如何影响公司的定价策略和毛利率 [82] 问题3 **Elizabeth Anderson 提问** 询问公司的产能利用率和未来产能扩张计划 [84][85] **Jim Foster 回答** 解释公司在产能管理方面的策略,有一定的闲置产能可以满足未来需求增长,但人员招聘和培训可能是制约因素 [85]

Charles River Laboratories (CRL) reported $1.01 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.7%. EPS of $2.27 for the same period compares to $2.78 a year ago.The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $997.24 million. With the consensus EPS estimate being $2.05, the EPS surprise was +10.73%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...

Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2024 RESULTS – First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – WILMINGTON, MA, May 9, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023. Th ...

财务表现 - 分析师预计Charles River Laboratories (CRL) 下一季度每股收益为$2.05，同比下降26.3% [1] - 预计营收为$997.24百万美元，同比下降3.1% [1] - 'Revenues- Research Models and Services' 有望达到$202.98百万美元，同比增长1.6% [7] - 'Revenues- Discovery and safety assessment' 预计将达到$625.40百万美元，同比下降5.6% [7] - 'Revenues- Manufacturing support' 预计将达到$169.61百万美元，同比增长1.4% [8] - 'Revenues- Services' 预计将达到$834.54百万美元，同比下降2.7% [9] - 'Revenues- Products' 预计将达到$162.38百万美元，同比下降5.6% [10] - 'Operating income- Research Models and Services Non-GAAP' 预计将达到$49.89百万美元，较上一年同期的$46.73百万美元有所增长 [10] - 'Operating income- Discovery and safety assessment - Non-GAAP' 预计将达到$146.73百万美元，较去年同期的$191.97百万美元有所下降 [11]